Aligos Therapeutics grants 42,300 non-qualified stock options to new hires.

Aligos Therapeutics, a biopharmaceutical company, has granted non-qualified stock options to purchase 42,300 shares of its stock to newly hired employees. The options were granted pursuant to the company's 2024 Inducement Plan and were made as an inducement to enter employment. The exercise price per share is equal to the closing price on the Grant Date.

Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral diseases, has announced the granting of non-qualified stock options to newly hired employees. The options, totaling 42,300 shares, were approved by the Compensation Committee on August 12, 2025, under the company's 2024 Inducement Plan. The exercise price per share is set at the closing price of Aligos' common stock on the grant date, in compliance with Nasdaq Listing Rule 5635(c)(4).

The shares will vest over a four-year period, with 25% vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments, subject to continued employment through the applicable vesting dates. These grants are exclusively for new hires, as per the company's policy.

The announcement comes as Aligos continues to expand its pipeline and advance its mission to improve patient outcomes through best-in-class therapies for liver and viral diseases. The company's recent progress includes the initiation of the Phase 2 B-SUPREME study of ALG-000184 for chronic hepatitis B virus (HBV) infection and the positive Phase 2a HERALD data for ALG-055009, its MASH treatment candidate.

For more information, please visit [Aligos Therapeutics' official website](https://www.aligos.com) or follow them on LinkedIn or X.

References:

[1] https://www.stocktitan.net/news/ALGS/aligos-therapeutics-announces-inducement-grants-under-nasdaq-listing-rtyi1dntd2za.html
[2] https://www.stocktitan.net/news/ALGS/